OncRef

Clinical Trial: NCT04736173

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Arcus Biosciences, Inc.
Information Provided By:Arcus Biosciences, Inc.
Last Update Posted:2026-10-19

Study Overview

Brief Summary

This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).

Official Title

Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Conditions

Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer

Intervention / Treatment

  • Drug: Domvanalimab
  • Drug: Zimberelimab
  • Drug: Carboplatin
  • Drug: Paclitaxel
  • Drug: Pemetrexed
  • Drug: Pembrolizumab

Other Study ID Numbers

  • ARC-10
  • 2020-003562-39
  • PHRR210222-003371
  • 2022-503071-28-00

Start Date (Actual)

2021-02-08

Primary Completion Date (Actual)

2026-09-17

Study Completion Date (Actual)

2026-09-17

Enrollment (Actual)

169

Study Type

Interventional

Phase

Phase 2